We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
New data from Novo Nordisk has shown that people with type I or type II diabetes who were switched to Tresiba (insulin degludec) by their doctor from other basal insulins achieved significantly reduced rates of hypoglycaemia, along with reduction in blood
New data from Novo Nordisk has shown that people with type I or type II diabetes who were switched to Tresiba (insulin degludec) by their doctor from other basal insulins achieved significantly reduced rates of hypoglycaemia, along with reduction in blood